drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy; allogeneic CAR-T)
drug_description
Allogeneic, gene-edited CD19-directed CAR T-cell therapy that retains endogenous TCR and knocks out SPPL3 (Power3) to reduce alloreactivity and improve persistence; mediates CD19-specific cytotoxicity against malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, gene-edited CD19-directed CAR T cells that recognize CD19 on malignant B cells to induce T-cell activation and cytotoxic killing. The product retains the endogenous TCR to support signaling and persistence, while SPPL3 (Power3) knockout reduces alloreactivity and host-mediated rejection, enhancing expansion and durability of the donor CAR T cells.
drug_name
ATHENA-2 CAR-T (allogeneic CD19 CAR-T with SPPL3 knockout; TCR retained)
nct_id_drug_ref
NCT06323525